The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

The TCTMD journalists look back at the year's memorable moments—and take a few guesses at what's ahead.

Cardiovascular imaging, which continues to evolve alongside interventions and other technologies, made notable strides in the ...

Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.

Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.

New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.

The Volt pulsed-field ablation (PFA) system (Abbott) has been approved by the US Food and Drug Administration for the treatment of patients with atrial fibrillation (AF), according to a Monday ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.